An innovative phase 2 clinical trial led by Dana-Farber Cancer Institute in collaboration with 10 major brain tumor centers around the country and designed to find new potential treatments for glioblastoma has reported initial results in the Journal of Clinical Oncology. While none of the three therapeutics tested so far improved overall survival of patients, this adaptive platform trial, the first of its kind in neuro-oncology, has the potential to rapidly and efficiently identify therapies that benefit patients.
Research potentially expands options for patients with aggressive childhood cancer
Research is shedding light and potentially expanding options for patients living with Medulloblastoma, an aggressive childhood cancer.
January 9, 2024